Abstract
A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on hemophiliacs, by using multiple serological markers and the polymerase chain reaction (PCR). Twenty-nine hemophiliacs, negative for HIV antibodies, were treated for 18 months with a concentrate that had been inactivated by solvent-detergent. HIV-1 antibodies and antigen were assayed during the follow-up period. At the end of the study, all patients were also tested by the HIV 1+2 combined antibody assay; Western blot (WB) antibody analysis; and in eight cases, by an HIV-1 PCR technique. Patients received a yearly median FVIII dose of 35,330 IU (range 3,300-306,000); the median number of lots given to each patient was 6 (1-45). During the follow-up period and at the end of the study, HIV-1 antibodies and antigen were not detected in any of the subjects. The HIV 1+2 combined assay and WB analysis carried out only at the end of the study were negative. HIV-1 PCR was negative in all the tested patients. This study was shown that this solvent-detergent-treated FVIII concentrate did not transmit HIV.
| Original language | English |
|---|---|
| Pages (from-to) | 71-74 |
| Number of pages | 4 |
| Journal | Journal of Medical Virology |
| Volume | 36 |
| Issue number | 2 |
| Publication status | Published - 1992 |
Fingerprint
Keywords
- Chemical inactivation
- HIV safety
- HIV-1 PCR
- Viral inactivation
ASJC Scopus subject areas
- Virology
Cite this
Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate. / Di Paolantonio, T.; Mariani, G.; Chirardini, A.; Gringeri, A.; Mannuccio Mannucci, P.; Mastrullo, L.; De Biasi, R.; Giustarini, G.; Morfini, M.; Schiavoni, M.; Ciavarella, N.; Zehender, G.; Zanetti, A. R.
In: Journal of Medical Virology, Vol. 36, No. 2, 1992, p. 71-74.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low risk of transmission of the human immunodefiency virus by a solvent-detergent-treated commercial factor VIII concentrate
AU - Di Paolantonio, T.
AU - Mariani, G.
AU - Chirardini, A.
AU - Gringeri, A.
AU - Mannuccio Mannucci, P.
AU - Mastrullo, L.
AU - De Biasi, R.
AU - Giustarini, G.
AU - Morfini, M.
AU - Schiavoni, M.
AU - Ciavarella, N.
AU - Zehender, G.
AU - Zanetti, A. R.
PY - 1992
Y1 - 1992
N2 - A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on hemophiliacs, by using multiple serological markers and the polymerase chain reaction (PCR). Twenty-nine hemophiliacs, negative for HIV antibodies, were treated for 18 months with a concentrate that had been inactivated by solvent-detergent. HIV-1 antibodies and antigen were assayed during the follow-up period. At the end of the study, all patients were also tested by the HIV 1+2 combined antibody assay; Western blot (WB) antibody analysis; and in eight cases, by an HIV-1 PCR technique. Patients received a yearly median FVIII dose of 35,330 IU (range 3,300-306,000); the median number of lots given to each patient was 6 (1-45). During the follow-up period and at the end of the study, HIV-1 antibodies and antigen were not detected in any of the subjects. The HIV 1+2 combined assay and WB analysis carried out only at the end of the study were negative. HIV-1 PCR was negative in all the tested patients. This study was shown that this solvent-detergent-treated FVIII concentrate did not transmit HIV.
AB - A study evaluating the risk of a commercial factor VIII (FVIII) concentrate's transmitting the human immunodeficiency virus (HIV) was carried out on hemophiliacs, by using multiple serological markers and the polymerase chain reaction (PCR). Twenty-nine hemophiliacs, negative for HIV antibodies, were treated for 18 months with a concentrate that had been inactivated by solvent-detergent. HIV-1 antibodies and antigen were assayed during the follow-up period. At the end of the study, all patients were also tested by the HIV 1+2 combined antibody assay; Western blot (WB) antibody analysis; and in eight cases, by an HIV-1 PCR technique. Patients received a yearly median FVIII dose of 35,330 IU (range 3,300-306,000); the median number of lots given to each patient was 6 (1-45). During the follow-up period and at the end of the study, HIV-1 antibodies and antigen were not detected in any of the subjects. The HIV 1+2 combined assay and WB analysis carried out only at the end of the study were negative. HIV-1 PCR was negative in all the tested patients. This study was shown that this solvent-detergent-treated FVIII concentrate did not transmit HIV.
KW - Chemical inactivation
KW - HIV safety
KW - HIV-1 PCR
KW - Viral inactivation
UR - http://www.scopus.com/inward/record.url?scp=0026585223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026585223&partnerID=8YFLogxK
M3 - Article
C2 - 1583469
AN - SCOPUS:0026585223
VL - 36
SP - 71
EP - 74
JO - Journal of Medical Virology
JF - Journal of Medical Virology
SN - 0146-6615
IS - 2
ER -